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It is with a great pleasure that we present the Readers 
with another issue of the Gland Surgery, which is this time 
dedicated solely to new techniques and technologies for 
the treatment of surgical endocrine diseases. Owing to the 
close international collaboration we are presenting in this 
issue 12 reports from leading experts in the field focused 
on selected hot topics in endocrine surgery: intraoperative 
neural monitoring (IONM) in thyroid surgery (1,2), 
safety of energy based devices (EBD) for hemostasis in 
thyroid surgery (3), utility of BRAF V600E mutation 
for prognostication of papillary thyroid cancer (PTC) 
recurrence (4), rare cases of PTC associated with thyroid 
Langerhans cell histiocytosis (5), management of thyroid 
cancer with tracheal invasion (6), utility of indocyanine 
green-enhanced fluorescence to assess parathyroid perfusion 
during thyroidectomy (7), value of iPTH assay for early 
prognostication of postoperative hypocalcemia (8), risk 
factors for perioperative hemodynamic instability in 
patients undergoing laparoscopic adrenalectomy for 
pheochromocytoma (9), utility of laparoscopic sleeve 
gastrectomy (LSG) for the treatment of diabetes mellitus 
type 2 (10), innovative solutions in bariatric surgery (11), 
including new endoscopic procedures for diabetes mellitus 
type 2 and obesity treatment (12).
Recurrent laryngeal nerve (RLN) injury remains 
a significant morbidity associated with thyroid and 
parathyroid surgery. In the past decade, surgeons have 
increasingly used IONM as an adjunct technique for 
localizing and identifying the RLN, detecting RLN injury, 
and predicting the outcome of vocal cord function. In recent 
years, many animal studies have investigated common 
pitfalls and new applications of IONM. For example, the 
use of IONM technology in animal models has proven 
valuable in studies of the electrophysiology of RLN injury. 
The advent of animal studies has substantially improved 
understanding of IONM technology. Lessons learned 
from animal studies have immediate clinical applications in 
establishing reliable strategies for preventing intraoperative 
RLN injury (1). 
Reoperative thyroid surgery remains most challenging 
even for skilled surgeons, and is associated with a higher 
incidence of complications, such as hypoparathyroidism 
and RLN palsy (2). Despite lacking hard evidence that 
IONM can diminish prevalence of permanent vocal fold’s 
palsy as many as 95.7% of the respondents of the most 
recent International Survey on the Identification and 
Neural Monitoring of the EBSLN During Thyroidectomy 
expressed their confidence in IONM and listed reoperative 
thyroid cases as the top indication far ahead all other clinical 
situations for utilization of this technique during thyroid 
surgery (13). Considering the wide availability of EBD more 
nerve injuries caused by thermal spread are expected in the 
near future if a strict standardized use is not applied. EBDs 
are unsafe in the close proximity the RLN. It is important 
not to directly touch the nerve with EBS immediately 
after the latter has been used. RLN must be well visualized 
before the activation. Experimental histological studies 
of vessel sealed with EBD demonstrated 1.5 to 3.3 mm 
thermal spread, beyond the tissue within the forceps’ jaws. 
Hence it was suggested not to use the device closer than 3 mm 
to the RLN (3). 
Despite excellent prognosis PTC involves a risk of 
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persistent or recurrent disease is up to 30% of patients. 
Currently, BRAF V600E mutation was evaluated in many 
studies as a possible prognostic marker for recurrence. 
However, outcome of these studies are conflicting, and 
prognostic significance of BRAF mutation was confirmed 
in some single center studies, a few meta-analyses and 
a large multicenter retrospective international study. At 
present, it seems that BRAF mutation is one of the factors 
influencing the prognosis and it should be analyzed in 
correlation with other prognostic factors. The most recent 
ATA recommendations do not indicate a routine application 
of BRAF status for initial risk stratification in differentiated 
thyroid cancer due to a lack of evident confirmation of a 
direct influence of mutation on the increase in relapse risk. 
However, ATA demonstrates the continuous risk scale for 
the relapse risk assessment, considering BRAF and/or TERT 
status. At present, researchers are working on determining 
the role of BRAF mutation in patients from a low-risk group 
and its correlations with others molecular events. Currently, 
BRAF mutation cannot be used as a single, independent 
predictive factor. However, its usefulness in the context of 
other molecular and clinicopathological risk factors cannot 
be excluded. They may be used to make modern prognostic 
scales of relapse risk and be applied to individualized 
diagnostic and therapeutic strategy for PTC patients (4). 
With increasing utilization of total thyroidectomy 
there is increasing risk of transient and permanent 
hypoparathyroidism, which is considered to be one of 
the most common but still underestimated morbidity 
following thyroid surgery. Visual identification and 
preservation in situ of all parathyroid glands with intact 
vascular supply during surgery remains the standard 
preventive measures. However, few recent reports turn 
our attention to indocyanine green-enhanced fluorescence 
as a technique both facilitating parathyroids identification 
and their viability assessment intraoperatively due to its 
potential for evaluation of tissue perfusion in real-time 
intraoperative angiography (7). In addition, the correlation 
of low iPTH serum level few hours after surgery and risk 
of hypocalcemia was repeatedly reported in the literature. 
Hence, iPTH serum level ≥10 pg/mL can be considered as 
an important criterion allowing for a safe and early hospital 
discharge following total thyroidectomy (8). 
Hemodynamic instability is one of the most commonly 
d iagnosed adverse  event  in  pat ients  undergoing 
laparoscopic adrenalectomy for pheochromocytoma. 
Although it occurs mostly during surgery, a significant 
proportion of patients require vasopressor agents also in 
the postoperative period. There are several risk factors 
associated with increased incidence of hemodynamic 
instability. They are directly related to the tumor size and 
its hormonal activity. Appropriate preoperative assessment 
and treatment with antihypertensive drugs significantly 
reduces the incidence of hemodynamic changes during and 
after surgery, thus minimizing serious complications and 
mortality. Moreover, operative factors seem to play crucial 
role. Meticulous dissection and gentle and minimal tumor 
manipulation and early adrenal vein ligation lower their 
incidence. Laparoscopy in the case of pheochromocytoma 
is safe and feasible. It is not associated with higher risk of 
hemodynamic instability. Such approach does not carry 
additional risk also in larger tumors. To minimize morbidity 
and mortality a close cooperation between the surgeon and 
anesthetist is mandatory in every patient with suspected or 
confirmed pheochromocytoma (9).
The main answer to the worldwide obesity epidemic 
is the increase in the number of performed bariatric 
procedures. Type 2 diabetes and glucose metabolism 
abnormalities are one the most important effects of morbid 
obesity which lead to severe and chronic reduction in 
quality of health. High effectiveness of bariatric therapy 
for weight reduction and treatment of comorbidities has 
been proven in numerous studies. But it is yet still unclear 
which bariatric procedure should be chosen for diabetic 
patients in order to achieve the best results in diabetes 
remission. Surprisingly, even LSG leads to significant 
improvement in biochemical glucose homeostasis and can 
be considered as a method of treatment in morbidly obese 
patients with glucose metabolism abnormalities. However, 
LSG as a method of treatment for patients with clinical 
type 2 diabetes still needs some further observation (10). In 
addition, new endoscopic devices are emerging in bariatric 
surgery, such as intragastric balloon, endoscopic vertical 
gastroplasty, duodenal-jejunal bypass sleeve, or aspire 
assist system, but the long-term results are not satisfactory. 
Endoluminal methods are an intriguing strategy for weight 
regain after bariatric surgery, however, they require highly 
skilled and experienced endoscopists to obtain good results. 
Many devices are no longer commercially available, due to 
long validation procedures. New promising technologies 
are emerging on the horizon, including neuromodulation 
and esophageal stents. They must be vigorously studied 
and improved before implementation in the clinical 
practice (11). New endoscopic treatments for obesity 
are promising techniques for selected patients but each 
procedure should be individually tailored to the specific 
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patient in a multimodal personalized approach (12).
The papers presented in this issue illustrate only a tip of 
the iceberg of the new techniques and technologies for the 
treatment of surgical endocrine diseases. It is quite clear 
that progress in the field will shift our current practice from 
conventional surgical techniques to more sophisticated 
minimally invasive approaches and uti l izat ion of 
intraoperative quality control measures in order to improve 
quality of life of our patients.
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